Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains.
COVID-19 variants
SARS-CoV-2
T-cell responses to coronavirus
vaccination
Journal
Cytotherapy
ISSN: 1477-2566
Titre abrégé: Cytotherapy
Pays: England
ID NLM: 100895309
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
24
05
2021
revised:
23
06
2021
accepted:
09
07
2021
pubmed:
7
9
2021
medline:
12
1
2022
entrez:
6
9
2021
Statut:
ppublish
Résumé
Although most studies describing coronavirus disease 2019 vaccine responses have focused on antibodies, there is increasing evidence that T cells play a critical role. Here the authors evaluated T-cell responses in seronegative donors before and after vaccination to define responses to the severe acute respiratory syndrome coronavirus 2 reference strain as well as to mutations in the variant strains Alpha/B.1.1.7 and Beta/B.1.351. The authors observed enhanced T-cell responses to reference and variant spike strains post-vaccination.
Identifiants
pubmed: 34483067
pii: S1465-3249(21)00741-6
doi: 10.1016/j.jcyt.2021.07.006
pmc: PMC8411349
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
10-15Informations de copyright
Copyright © 2021. Published by Elsevier Inc.
Déclaration de conflit d'intérêts
Declaration of Competing Interest CL, MDK, CRYC and CMB have intellectual property related to developing T-cell therapies for infectious diseases, including SARS-CoV-2.